Sonia Moretti

Perugia, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Predictors of response to lenvatinib in advanced differentiated thyroid cancer: focus on the CONUT score.

Predictors of response to lenvatinib in advanced differentiated thyroid cancer: focus on the CONUT score.

Journal: Endocrine

Published: December 11, 2024

Wnt/B-catenin Activation and TP53 Mutations Associate With Distinct Immune Profiles in Advanced Thyroid Cancer.

Wnt/B-catenin Activation and TP53 Mutations Associate With Distinct Immune Profiles in Advanced Thyroid Cancer.

Journal: The Journal of clinical endocrinology and metabolism

Published: April 05, 2024

Turning a Tumor Microenvironment Pitfall into Opportunity: Discovery of Benzamidoxime as PD-L1 Ligand with pH-Dependent Potency.

Turning a Tumor Microenvironment Pitfall into Opportunity: Discovery of Benzamidoxime as PD-L1 Ligand with pH-Dependent Potency.

Journal: International journal of molecular sciences

Published: February 23, 2023

Impact of Epithelial-Mesenchymal Immunophenotype on Local Aggressiveness in Papillary Thyroid Carcinoma Invading the Airway.

Impact of Epithelial-Mesenchymal Immunophenotype on Local Aggressiveness in Papillary Thyroid Carcinoma Invading the Airway.

Journal: Journal of clinical medicine

Published: July 19, 2021

Immune Landscape of Thyroid Cancers: New Insights.

Immune Landscape of Thyroid Cancers: New Insights.

Journal: Frontiers in endocrinology

Published: December 04, 2020

PD-1 blockade delays tumor growth by inhibiting an intrinsic SHP2/Ras/MAPK signalling in thyroid cancer cells.

PD-1 blockade delays tumor growth by inhibiting an intrinsic SHP2/Ras/MAPK signalling in thyroid cancer cells.

Journal: Journal of experimental & clinical cancer research : CR

Published: October 23, 2020

The Stone Guest: How Does pH Affect Binding Properties of PD-1/PD-L1 Inhibitors?

The Stone Guest: How Does pH Affect Binding Properties of PD-1/PD-L1 Inhibitors?

Journal: ChemMedChem

Published: September 25, 2020

THERAPY OF ENDOCRINE DISEASE Immunotherapy of advanced thyroid cancer: from bench to bedside.

THERAPY OF ENDOCRINE DISEASE Immunotherapy of advanced thyroid cancer: from bench to bedside.

Journal: European journal of endocrinology

Published: April 01, 2020

The Aryl Hydrocarbon Receptor Is Expressed in Thyroid Carcinoma and Appears to Mediate Epithelial-Mesenchymal-Transition.

The Aryl Hydrocarbon Receptor Is Expressed in Thyroid Carcinoma and Appears to Mediate Epithelial-Mesenchymal-Transition.

Journal: Cancers

Published: December 12, 2019

Methylglyoxal Acts as a Tumor-Promoting Factor in Anaplastic Thyroid Cancer.

Methylglyoxal Acts as a Tumor-Promoting Factor in Anaplastic Thyroid Cancer.

Journal: Cells

Published: March 15, 2019

Immune Profiling of Thyroid Carcinomas Suggests the Existence of Two Major Phenotypes: An ATC-Like and a PDTC-Like.

Immune Profiling of Thyroid Carcinomas Suggests the Existence of Two Major Phenotypes: An ATC-Like and a PDTC-Like.

Journal: The Journal of clinical endocrinology and metabolism

Published: June 01, 2018

Long glucocorticoid-induced leucine zipper regulates human thyroid cancer cell proliferation.

Long glucocorticoid-induced leucine zipper regulates human thyroid cancer cell proliferation.

Journal: Cell death & disease

Published: August 02, 2017

Showing 1-12 of 20

Last Updated: 09/26/2026